MAPT and amyloidosis: Our diagnosis of dementia was based on clinical criteria rather than biomarker-based definitions (e.g., amyloid or tau deposition using cerebrospinal fluid analysis or brain positron emission tomography imaging), although our approach is more consistent with routine clinical practice in which CSF and PET data are not readily available.